期刊文献+

肺癌治疗性疫苗的临床应用进展 被引量:1

Clinical Development of Therapeutic Vaccine for Lung Cancer
下载PDF
导出
摘要 肿瘤疫苗即是利用肿瘤细胞或肿瘤抗原物质诱导机体的特异性细胞免疫和体液免疫反应,以调节机体免疫功能,达到治疗肿瘤的目的。治疗性肿瘤疫苗可通过主动免疫诱导全身特异性抗肿瘤效应。根据其制备方法不同,疫苗主要分为:细胞疫苗、多肽疫苗和蛋白质疫苗、核酸疫苗、抗独特型抗体疫苗等。本文对目前肺癌相关疫苗的类型、研究进展和临床应用情况进行综述,从而为进一步的研究提供一定的借鉴和参考。 Tumor vaccine is the use of tumor cells or tumor antigen to induce the specific cellular immunity and humoral immunity to regulate immune function, and achieve the purpose of treatment tumors. Therapeutic tumor vaccine can induce the specific anti-tumor effect of the whole body by active immunization. According to the different preparation methods, tumor vaccine is divided into:cell vaccines, peptide and protein vaccines, nucleic acids vaccine, anti-idiotypic antibody vaccine et al. This article reviewed the type of lung cancer vaccine, research progress and clinical application,so as to provide a further reference to the future research.
出处 《医学综述》 2009年第18期2777-2779,共3页 Medical Recapitulate
关键词 肺癌 疫苗 治疗性疫苗 Lung cancer Vaccine Therapeutic vaccine
  • 相关文献

参考文献18

  • 1王洪武.肺癌疫苗的研究现状[J].临床肿瘤学杂志,2005,10(3):323-326. 被引量:2
  • 2Nemunaitis J,Jahan T,Ross H,et al.Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer[J].Cancer Gene Ther,2006,13(6):555-562.
  • 3Nemunaitis J.GVAX(GM-CSF gene modified tumor vaccine)in advanced stage non-small cell lung cancer[J].J Control Release,2003,91(1/2):225-231.
  • 4Nemunaitis J,Sterman D,Jablons D,et al.Granulocyte-macro-phage colony-stimulating factor gene-modified autologous tumor vaccines in non-small cell lung cancer[J].J Natl Cancer Inst,2004,96(4):326-331.
  • 5Nemunaitis J,Dillman RO,Schwarzenberger PO,et al.Phase II study of belagenpumatucel-L,a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer[J].J Clin Oncol,2006,24(29):4721-4730.
  • 6谢晓原,陈俊辉.肿瘤疫苗研究进展及应用现状[J].医学综述,2007,13(12):896-898. 被引量:2
  • 7Atanackovic D,Altorki NK,Stockert E,et al.Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients[J].J Immunol,2004,172(5):3289-3296.
  • 8Ramos TC,Vinageras EN,Ferrer MC,et al.Treatment of NSCLC patients with an EGF-based cancer vaccine:report of a Phase I trial[J].Cancer Biol Ther,2006,5(2):145-149.
  • 9González G,Crombet T,Neninger E,et al.Therapeutic vaccination with epidermal growth factor(EGF)in advanced lung cancer:analysis of pooled data from three clinical trials[J].Hum Vaccin,2007,3(1):8-13.
  • 10Nakajima H,Kawasaki K,Oka Y,et al.WTl peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WTl peptide vaccination alone[J].Cancer Immunol Immunother,2004,53(7):617-624.

二级参考文献36

  • 1刘宏利,赵建平,倪兵,贾正才,周伟,邹丽云,吴玉章.新型颗粒性肽-DNA复合疫苗有效激发肿瘤抗原特异性CTL反应[J].免疫学杂志,2004,20(4):247-250. 被引量:2
  • 2J Nemunaitis. GVAX (GM-CSF gene modified tumor vaccine)in advanced stage non -small cell lung cancer[J]. J Control Release, 2003,91(1-2):225-231.
  • 3Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small cell lung cancer[J]. J National Cancer Institute, 2004,94(4):326-331.
  • 4Raez LE, Cassi leth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small cell lung cancer[J]. J Clin Oncol, 2004,22(14):2800-2807.
  • 5M Palmer, J Parker, S Modi, et al. Phase I study of the BLP25(MUC-1 peptide) "liposomal vaccine for active specific immmunotherapy in stage ⅢB/IV non-small cell lung cancer[J]. Clin Lung Cancer, 2001,30:49-57.
  • 6Squiban P, Velu T, Menecier B, et al. MVA-MUC1-IL2 vaccine immunotherapy for advanced non-small cell lung cancer (NSCLC): Interim phase Ⅱ data[J]. J Clin Oncol, 2004,22(14S):2544.
  • 7Krug LM, Ragupathi G, Ng KK, et al. Vaccination of small cell lung cancer patients with polysialic acid or N-Propionylated polysialic acid conjugated to Keyhole Limpet Hemoeyanin[J]. Clin Cancer Res, 2004,10:916-923.
  • 8Krug LM, Ragupathi G, Hood C, et al. Vaccination of patients with small-cell lung cancer with Synthetic Fucosy1 GM-1 conjugated to Keyhole Limpet Hemocyanin[J]. Clinical Cancer Res, 2004,10:6094-6100.
  • 9Giaccone G, Debruyne C, Felip F, et al. Phase Ⅲ study of BEC2/BCG vaccinatio in limited disease small cell lung cancer(LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study)[J]. J Clin Oncol, 2004,22(14S):7020.
  • 10Ueda Y, Itoh T, Nukaya I, et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas[J]. Int J Oncol, 2004,24(4):909-917.

共引文献2

同被引文献24

  • 1Kiessling R, Ljungberg K, Von Gabain A.Therapeutic vaccines against cancer and infectious diseases.Great possibilities in the research-small clinical progress so far[J].Lakartidningen, 2008, 105 ( 36 ): 2402-2404.
  • 2Elizaga ML, Mcelrath MJ.Progress in the development of a preventive HIV-1 vaccine[J].Clin Lab Med,2002,22 ( 4 ) : 963-980.
  • 3Vandepapeliere P, Lau GK, Leroux-Roels G, et al.Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy:a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine[J].Vaecine, 2007,25 ( 51 ) : 8585-8597.
  • 4Raices M.NASVAC: a therapeutic vaccine with potentialities to improve the quality of life of chronic hepatitis B patients[J].Biotecnolog I a Aplicada,2003, 3 (28): 168-169.
  • 5Couillin I, Pol S, Mancini M, et al.Specific vaccine therapy in chronic hepatitis B:induction of T cell proliferative responses specific for envelope antigens[J].J Infect Dis, 1999, 180 ( 1 ) : 15-26.
  • 6Kim CY, Kang ES, Kim SB, et al.Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation[J].Exp Mol Med,2008,40 ( 6 ): 669-676.
  • 7Kladc CS, Wedemeycr H, Berg T, et al.Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41[J]. Gastroenterology, 2008,134 ( 5 ) : 1385-1395.
  • 8Bacardi D, Amador-Canizares Y, Cosme K, at al.Toxicology andbiodistribution study of CIGB-230,a DNA vaccine against hepatitis C virus[J]. Hum Exo Toxicol,2009,28 ( 8 ) : 479-491.
  • 9Forde KA, Reddy KR.Hepatitis C virus infection and immunomodulatory therapies[J].Clin Liver Dis,2009, 13 ( 3 ): 391-401.
  • 10Pereira AA, Jacobson IM.New and experimental therapies for HCV[J].Nat Rev Gastroenterol Hepatol,2009,6 ( 7 ): 403-411.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部